Search
Displaying 461–470 of 737 for “retinitis clinical trial”
-
Individual Investigator Research Award (IIRA)
Individual Investigator Research Awards are designed to concentrate research in areas with the greatest potential to move toward treatments and cures for the inherited orphan retinal degenerative diseases and dry age-related macular degeneration. This award provides approximately $100,000 per year up to three (3) years. These opportunities seek candidates that hold a Ph.D., M.D., M.D./Ph.D., D.M.D., D.V.M., D.O., O.D., or equivalent degree and have a faculty position or equivalent at a domestic or foreign: non-profit organization, or public or private institution, such as a university, college, medical school, hospital, research institute, or laboratory. Individuals from underrepresented racial, ethnic and gender groups, as well as individuals with disabilities, are always encouraged to apply.
-
Foundation News
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
In the Press
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
Foundation Fighting Blindness Applauds Introduction of LOANS for Biomedical Research Act
Foundation NewsLegislation provides innovative financing for clinical trials stalled by COVID-19 pandemic.
-
Pioneering Delivery Strategies for Blinding Diseases Therapy and Inspiring Women in Science
Beacon StoriesInternational Day of Women and Girls in Science is celebrated globally to recognize the critical role women play in science, technology, engineering, and mathematics. To honor this vital day, the Foundation is thrilled to spotlight Dr. Renee Ryals, PhD, a remarkable scientist at the Casey Eye Institute, Oregon Health & Science University.
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
Research NewsMore than 8,000 people have applied for genetic testing through the Foundation’s program
-
In the Press
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
-
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
Foundation NewsNew grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
Information for Newly Diagnosed Patients and their Loved Ones
-
Foundation News
Three-day conference in San Diego will feature retinal science’s leading researchers and clinicians, and focus on the year’s top science and emerging treatments
